Roivant (ROIV) reported financial results for the first quarter ended June 30, 2026, including revenue of $1.4 million and a net loss of $290.6 million. Net loss per common share was $0.26 on a basic and diluted basis.
The company reported consolidated cash, cash equivalents, restricted cash and marketable securities of $3.9 billion as of June 30, 2026, excluding the cash payment received from Moderna in July.
- Brepocitinib commercial preparations in dermatomyositis remain on track for launch by the end of September 2026.
- Topline data are expected in the second half of calendar 2026 from studies in non-infectious uveitis, pulmonary hypertension associated with interstitial lung disease and cutaneous lupus erythematosus.
- Genevant and Arbutus received $950 million from Moderna in July 2026 under a $2.25 billion settlement, with an additional $1.3 billion contingent on Moderna’s Section 1498 appeal.
- Roivant repurchased 7.3 million common shares for approximately $208.7 million during the quarter.
- R&D expenses rose to $202.0 million, while G&A expenses rose to $165.5 million for the quarter.
$ROIV Insider Trading Activity
$ROIV insiders have traded $ROIV stock on the open market 51 times in the past 6 months. Of those trades, 0 have been purchases and 51 have been sales.
Here’s a breakdown of recent trading of $ROIV stock by insiders over the last 6 months:
- KEITH S MANCHESTER has made 0 purchases and 11 sales selling 2,863,947 shares for an estimated $89,102,593.
- FRANK TORTI (President and Vant Chair) has made 0 purchases and 3 sales selling 3,000,000 shares for an estimated $82,039,460.
- FINANCIAL LP QVT has made 0 purchases and 10 sales selling 2,663,947 shares for an estimated $82,012,593.
- DANIEL ALLEN GOLD has made 0 purchases and 10 sales selling 2,663,947 shares for an estimated $82,012,593.
- MAYUKH SUKHATME (President & CIO) has made 0 purchases and 3 sales selling 1,339,441 shares for an estimated $43,090,003.
- ERIC VENKER (President & Immunovant CEO) has made 0 purchases and 7 sales selling 1,200,000 shares for an estimated $36,539,267.
- MATTHEW GLINE (CEO) sold 289,774 shares for an estimated $8,449,809
- MEGHAN FITZGERALD has made 0 purchases and 2 sales selling 80,000 shares for an estimated $2,270,500.
- MELISSA B, EPPERLY has made 0 purchases and 3 sales selling 59,611 shares for an estimated $1,810,825.
- JENNIFER HUMES (Chief Accounting Officer) sold 13,538 shares for an estimated $384,073
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ROIV Hedge Fund Activity
We have seen 272 institutional investors add shares of $ROIV stock to their portfolio, and 158 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SB INVESTMENT ADVISERS (UK) LTD removed 13,741,871 shares (-83.7%) from their portfolio in Q1 2026, for an estimated $380,649,826
- FMR LLC added 12,201,789 shares (+18.5%) to their portfolio in Q1 2026, for an estimated $337,989,555
- FARALLON CAPITAL MANAGEMENT LLC added 9,638,000 shares (+26048.6%) to their portfolio in Q1 2026, for an estimated $266,972,600
- DARWIN GLOBAL MANAGEMENT, LTD. added 6,797,300 shares (+inf%) to their portfolio in Q1 2026, for an estimated $188,285,210
- MORGAN STANLEY removed 6,531,228 shares (-11.2%) from their portfolio in Q1 2026, for an estimated $180,915,015
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 5,561,714 shares (+76.9%) to their portfolio in Q1 2026, for an estimated $154,059,477
- AQR CAPITAL MANAGEMENT LLC added 5,066,085 shares (+575.2%) to their portfolio in Q1 2026, for an estimated $140,330,554
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
